Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 Months Cognition Improved 3.0 Points on ADAS-Cog at 9 Months ( p
Simufilam Significantly Improved Biomarkers in Alzheimer’s Patients Treated for 6 Months Robust Improvements Seen in All Measured Biomarkers of Disease, Neurodegeneration and Neuroinflammation (p
SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam Treatment Simufilam 100 mg and 50 mg Reduced Plasma Levels of Altered Filamin A in Alzheimer’s Patients 48% (p=0.003) and 44% (p=0.02) Respectively Plasma
- On Monday, July 26 th , New Clinical Data for SavaDx to be Shared in a Poster Presentation - - On Thursday, July 29 th , New Clinical Data for Simufilam to be Featured in a Podium Presentation - AUSTIN, Texas , July 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer’s Disease AUSTIN, Texas , June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced
Open-label Study Completes Patient Enrollment Cognition Maintenance Study Initiated May 2020 , now 30% Enrolled 6-month Biomarker Data to be Presented at AAIC Conference in July 9-month Safety & Cognition Data to be Presented at AAIC Conference Clinical Results with SavaDx to be Presented at AAIC
AUSTIN, Texas , June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference , a virtual event taking
- Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals – AUSTIN, Texas , June 14, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced
- Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time - - Discussion to be Moderated by Jason McCarthy , PhD, Head of Biotechnology Research at Maxim Group - AUSTIN, Texas , May 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology
- Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - AUSTIN, Texas , May 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it
